glp 1 agonist inflammation The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists Bridging the gap between GLP1-receptor

All of the patients had been diagnosed with an autoimmune disease and obesity, and researchers analyzed more than 10 years of their health data

If these effects translate to humans, GLP-1 medications could theoretically slow neurodegenerative processes

Myo-inositol trispyrophosphate (ITPP) was declared prohibited in 2012

Naruse M, Naruse K, Yoshimoto T, et al

Funding Nil

The CANVAS (Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes) trial revealed lower risk for death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke in patients with established type 2 diabetes and cardiovascular disease treated with canagliflozin in comparison to placebo